Antroquinonol for COVID-19: real-time analysis

Download Image

Post

c19early.org

Antroquinonol for COVID-19

1 study with 124 patients

Serious outcome risk

Antroquinonol

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Antroquinonol studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−200%

Hospitalization (1)2%

Viral clearance (1)7%

RCTs (1)−200%

Late (1)−200%

00.511.5+

← Antroquinonol
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Antroquinonol is an orally administered small molecule, isolated from Antrodia camphorata, with anti-inflammatory and potential antiviral activity.


Dec 23 2021	Cheng et al., NCT04523181	A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19
Dec 23 2021	200% higher progression (p=1), 17% slower recovery (p=0.72), 2% shorter hospitalization (p=0.92), and 7% faster viral clearance (p=0.87). RCT 124 hospitalized COVID-19 patients showing no significant differences with antroquinonol.